We have located links that may give you full text access.
Helicobacter pylori infection as predictor of treatment outcomes of gastric cancer: a systematic review and metanalysis.
Digestive Diseases 2023 March 11
BACKGROUND: Helicobacter pylori infection is strongly associated with gastric cancer. However, there is currently no consensus on the association between H. pylori and gastric cancer prognosis.
METHODS: A systematic search was conducted on studies in PubMed, EMBASE, and Web of Science up to March 10, 2022. The quality of all included studies was assessed using the Newcastle-Ottawa Scale. The hazard ratio (HR) and its 95% confidence interval (95%CI) were extracted to analyze the association between H. pylori infection and prognosis of gastric cancer. In addition, subgroup analysis and publication bias were performed.
RESULTS: A total of 21 studies were involved. The pooled HR was 0.67 (95%CI, 0.56-0.79) for overall survival (OS) in H. pylori-positive patients, with the control (HR=1) being the H. pylori-negative group. In the subgroup analysis, the pooled HR was 0.38 (95%CI, 0.24-0.59) for OS in H. pylori-positive patients who received surgery combined with chemotherapy. The pooled HR for disease-free survival was 0.74 (95%CI, 0.63-0.8), and 0.41 (95%CI, 0.26-0.65) in patients received surgery combined with chemotherapy.
CONCLUSIONS: H. pylori-positive gastric cancer patients have a better overall prognosis than negative patients. Helicobacter pylori infection has improved the prognosis of patients undergoing surgery or chemotherapy, among which the improvement was most obvious in patients undergoing surgery combined with chemotherapy.
METHODS: A systematic search was conducted on studies in PubMed, EMBASE, and Web of Science up to March 10, 2022. The quality of all included studies was assessed using the Newcastle-Ottawa Scale. The hazard ratio (HR) and its 95% confidence interval (95%CI) were extracted to analyze the association between H. pylori infection and prognosis of gastric cancer. In addition, subgroup analysis and publication bias were performed.
RESULTS: A total of 21 studies were involved. The pooled HR was 0.67 (95%CI, 0.56-0.79) for overall survival (OS) in H. pylori-positive patients, with the control (HR=1) being the H. pylori-negative group. In the subgroup analysis, the pooled HR was 0.38 (95%CI, 0.24-0.59) for OS in H. pylori-positive patients who received surgery combined with chemotherapy. The pooled HR for disease-free survival was 0.74 (95%CI, 0.63-0.8), and 0.41 (95%CI, 0.26-0.65) in patients received surgery combined with chemotherapy.
CONCLUSIONS: H. pylori-positive gastric cancer patients have a better overall prognosis than negative patients. Helicobacter pylori infection has improved the prognosis of patients undergoing surgery or chemotherapy, among which the improvement was most obvious in patients undergoing surgery combined with chemotherapy.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app